Hyperleukocytosis complicating lonafarnib treatment in patients with chronic myelomonocytic leukemia [10]

Leukemia

Volumn 19, Issue 2, 2005, Pages 308-310

  Buresh, A ^a   Perentesis, J ^b   Rimsza, L ^a   Kurtin, S ^a   Heaton, R ^a,c   Sugrue, M ^d   List, A ^a,c  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; CORTICOSTEROID; DEXAMETHASONE; ETOPOSIDE; K RAS PROTEIN; LONAFARNIB; MITOGEN ACTIVATED PROTEIN KINASE; OXYGEN; RETINOIC ACID; THALIDOMIDE; TIPIFARNIB;

ACUTE GRANULOCYTIC LEUKEMIA; BODY WEIGHT DISORDER; BONE MARROW EXAMINATION; CELL ADHESION; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL TRIAL; DIARRHEA; DRUG WITHDRAWAL; DYSPNEA; HUMAN; HYPERLEUKOCYTOSIS; HYPOKALEMIA; HYPOXEMIA; LABORATORY TEST; LETTER; LEUKEMIA CELL; LEUKEMOGENESIS; LEUKOCYTE COUNT; LEUKOCYTOSIS; LUNG SEQUESTRATION; MONOCYTOSIS; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; ONCOGENE K RAS; OXYGEN THERAPY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS IN TRANSFORMATION; RESPIRATORY DISTRESS; SYMPTOMATOLOGY; THORAX RADIOGRAPHY; THROMBOCYTOPENIA;

EID: 13544275900     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403569     Document Type: Letter

References (8)

1. De Botton S, Dombret H, Sanz M, San Miguel J, Caillot D, Zittoun R, et al., The European APL Group. Incidence, clinical feature, and outcome of the all-trans retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. Blood 1998; 92 2712-2718.
2. Larson RS, Brown DC, Sklar LA. Retinoic acid induces aggregation of the acute promyelocytic leukemia cell line NB-4 by utilization of LFA-1 and ICAM-2. Blood 1997; 90: 2747-2756.
3. Maloisel F, Petit T, Kessler R, Oberling F. Cytologic examination of broncho-alveolar lavage fluid in all-trans retinoic acid syndrome. Eur J Haematol 1996; 56: 319-320.
4. Camacho LH, Soignet SL, Chanel S, Ho R, Heller G, Scheinberg DA et al. Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide. J Clin Oncol 2000; 18: 2620-2625.
5. Nagafuji K, Eto T, Tokunaga Y, Hayashi S, Niho Y. Retinoic acid syndrome during treatment of acute myelomonocytic leukemia with all-trans retinoic acid and low dose ARA-C. Br J Haematol 1998; 100: 610-611.
6. Reuter CWM, Morgan MA, Bergmann L. Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies? Blood 2000; 96: 1655-1669.
7. Cortes J, Albitar M, Thomas D, Giles F, Kurzrock R, Thibault A et al. Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood 2003; 101: 1692-11977.
8. Hughes PE, Renshaw RW, Pfaff M, Forsyth J, Keivens VM, Schwartz MA et al. Suppression of integrin activation: a novel function of a Ras/Raf-initiated MAP kinase pathway. Cell 1997; 88: 521-530.